Brief: Avalo Therapeutics Says First Patient Dosed in the Phase 2 Trial of AVTX-002 for Treatment of Non-Eosinophilic Asthma
18/05/2022 12:49
May 18 (Reuters) - Avalo Therapeutics Inc AVTX.O :
* AVALO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE 2
PEAK TRIAL OF AVTX-002 FOR THE TREATMENT OF NON-EOSINOPHILIC
ASTHMA (NEA)
Source text for Eikon: ID:nGNX50SjrP
Further company coverage: AVTX.O
((Reuters.Briefs@thomsonreuters.com;))